Table 1.
Patient # | Patient Age | Tumor Type | Tumor Grade (Nottingham) | Tumor Size | ER Status | PR Status | HER2 Status (IHC) | HER2 Status (FISH) | Nodal Status | TNM |
---|---|---|---|---|---|---|---|---|---|---|
107 | 68 | Ductal | I | 1.5×1.0×0.5 | ± (3/8) | − (0/8) | − (1/3) | N/A | 0 | pT1cN0MX |
109 | 80 | Mucinous | I | 2.8 × 1.1 | + (8/8) | ± (4/8) | − (0/3) | N/A | 0 | pT2NXMX |
113 | 53 | Ductal (Left) | I | 8.5×8.0×3.8 | + (5/8) | − (0/8) | − (0/3) | N/A | 0 | pTisN0MX |
Lobular (Right) | II | 5cm | + (8/8) | + (8/8) | ± (2/3) | − (0/3) | 0 | pT3N0MX | ||
129 | 65 | Ductal | II | 2.1cm | + (8/8) | + (7/8) | ± (2/3) | − (0/3) | Pos (0.56mm) micro FISH 1.3 |
pTpN1micpMX |
All tumor samples were de-identified at time of obtainment. Clinical pathology was performed and recorded for each patient. (ER) estrogen receptor, (PR) progesterone receptor, (Her2) human epidermal growth factor receptor 2, (TNM) tumor node metastasis, (IHC) Immunohistochemistry, (FISH) Fluorescence in situ hybridization.